Preventing CMV with CMVIG after conversion to belatacept in kidney transplant recipients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1/2, single‑center interventional study gives Cytogam (CMV immune globulin) to adult kidney transplant recipients who are CMV IgG–negative and received a CMV IgG–positive donor (D+/R-), either at the time of conversion from CNI‑based immunosuppression to belatacept or while stable on belatacept. Participants will receive scheduled CMVIG infusions and be followed for CMV infection, pharmacokinetics, and safety outcomes. The trial focuses on tolerability and whether CMVIG lowers CMV infection rates in this high‑risk population. All enrollment and follow‑up visits occur at the University of Minnesota.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult (18-70 year old) kidney transplant recipients
* Patients transitioning from conventional CNI-based immunosuppression to co-stimulatory blockade (belatacept) immunosuppression OR patients who are stable on belatacept immunosuppression at the time of initial CYTOGAM infusion
* CMV Ig Seronegative Recipient who received a CMV Ig seropositive Donor
* EBV IgG Positive

Exclusion Criteria:

* Pregnant people
* Subjects unwilling to sign consent and complete follow up visits
* Subjects with IgA immunodeficiency
* Subjects who are receiving IgG therapy or who have received IgG therapy within two months of study enrollment
* Patients who do not speak English and would need a translator and translated consent materials in order to obtain informed consent

Where it's running

• University of Minnesota
  Minneapolis, Minnesota, United States Recruiting

Study contacts

• Principal investigator: Vanessa Humphreville, MD — University of Minnesota
• Study coordinator: Elise Reed
• Email: surgcto@umn.edu
• Phone: 612-624-9695

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Omnisol-preserved kidneys before transplant (hypothermic machine perfusion)

  This study tests whether using Omnisol during hypothermic machine perfusion before kidney transplant can improve early graft function compared with standard preservation.

  Recruiting Vivalyx GmbH · Rotterdam · NCT07792317

• How Propofol and Sevoflurane Affect miRNA in Living Kidney Donors

  This study tests whether using propofol or sevoflurane during donor nephrectomy changes levels of miRNAs in living kidney donors.

  Recruiting University of Gaziantep · Gaziantep, Sahinbey · NCT07760402

• Effects of general vs spinal-epidural anesthesia on kidney transplant biomarkers

  This study tests whether sevoflurane general anesthesia or combined spinal-epidural anesthesia changes markers of cellular stress and protective peptides in adults undergoing kidney transplantation.

  Recruiting University of Gaziantep · Gaziantep, State/Province · NCT07678073

• How kidney transplant patients feel about using artificial intelligence in medicine

  This international survey asks adults who have had a kidney transplant how they feel about AI tools that predict graft loss and what it might mean for their daily care.

  Recruiting at 2 sites Paris Translational Research Center for Organ Transplantation · Paris, Île-de-France Region and 1 other locations · NCT07600541

• Personalized therapeutic stories for children after kidney transplant.

  We will test whether clinician-supervised AI can create age-appropriate, personalized therapeutic stories for children aged 5–12 who have received a kidney transplant and their families.

  Recruiting Paris Translational Research Center for Organ Transplantation · Paris, Île-de-France Region · NCT07532382

• Treating blood vessel problems after a kidney transplant

  This effort will try catheter-based angioplasty and advanced imaging to see if they help kidney transplant recipients with graft dysfunction or stubborn high blood pressure from possible transplant blood‑vessel problems.

  Recruiting at 3 sites University of Aarhus · Aarhus and 2 other locations · NCT07531966

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.